Xeris Pharmaceuticals Liabilities 2024

Xeris Pharmaceuticals Aktienanalyse

What does Xeris Pharmaceuticals do?

Xeris Pharmaceuticals Inc is a US pharmaceutical company that was founded in 2005. The company is headquartered in Chicago and is listed on the Nasdaq stock exchange. The business model of Xeris Pharmaceuticals is focused on providing patients and medical professionals with a wide range of products and services that improve patients' lives while promoting the development of effective and safe drugs. Xeris Pharmaceuticals focuses on the development of drugs made from peptides and proteins. The aim is to provide innovative drugs to patients with rare diseases or unmet therapeutic needs. Over the years, Xeris Pharmaceuticals has diversified into various sectors. One of the most important sectors is the diabetes industry. In this area, the company offers the Gvoke product family, a lightweight auto-injection method designed for adults, adolescents, and children with type 1 diabetes, as well as adults with type 2 diabetes. The Gvoke product is intended for patients with severe hypoglycemia and provides a quick and easy way to treat life-threatening hypoglycemic episodes. Another important sector for Xeris Pharmaceuticals is the neurology industry. In this area, the company has developed an injection device called XeriSol, specifically designed for the treatment of epilepsy or neurological seizures. The active ingredient used is diazepam, which has a rapid and reliable effect on seizures. Xeris Pharmaceuticals is also involved in cancer treatment. The company has developed a pituitary hormone analog called Pasireotide, which is used to treat Cushing's disease, a rare condition caused by hormone overproduction. The drug fits well into Xeris Pharmaceuticals' business model as it is peptide-based and offers better efficacy and safety than other drugs in this area. Overall, Xeris Pharmaceuticals has a strong pipeline of drugs that offer the company great potential for future growth. The development of innovative drugs and drug combinations is an important strategy for Xeris Pharmaceuticals to help patients with rare diseases or unmet therapeutic needs. In this regard, Xeris Pharmaceuticals has also formed partnerships with other leading pharmaceutical companies such as Sanofi, Eli Lilly, and Roche. These partnerships allow the company to accelerate its drug development and offer its products in the international market. In conclusion, the success story of Xeris Pharmaceuticals shows that the company is an important player in the pharmaceutical industry and plays a crucial role in the development of innovative, safe, and effective drugs for patients with rare diseases and unmet therapeutic needs. With its wide range of products, partnerships, and strong pipeline of innovative drugs, Xeris Pharmaceuticals is a company that has great potential for successful growth in the future. Xeris Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Xeris Pharmaceuticals's Liabilities

Xeris Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Xeris Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Xeris Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Xeris Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Xeris Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Xeris Pharmaceuticals stock

What is the level of liabilities of Xeris Pharmaceuticals this year?

Xeris Pharmaceuticals has a debt balance of 329.38 M USD this year.

What were the liabilities of Xeris Pharmaceuticals compared to the previous year?

The liabilities of Xeris Pharmaceuticals have increased by 10.05% increased compared to the previous year.

What are the consequences of high debt for investors of Xeris Pharmaceuticals?

High liabilities can pose a risk for investors of Xeris Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Xeris Pharmaceuticals?

Low liabilities mean that Xeris Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Xeris Pharmaceuticals affect the company?

An increase in liabilities of Xeris Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Xeris Pharmaceuticals affect the company?

A decrease in the liabilities of Xeris Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Xeris Pharmaceuticals?

Some factors that can influence the liabilities of Xeris Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Xeris Pharmaceuticals so important for investors?

The liabilities of Xeris Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Xeris Pharmaceuticals take to modify the liabilities?

To change its liabilities, Xeris Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Xeris Pharmaceuticals pay?

Over the past 12 months, Xeris Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Xeris Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Xeris Pharmaceuticals?

The current dividend yield of Xeris Pharmaceuticals is .

When does Xeris Pharmaceuticals pay dividends?

Xeris Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Xeris Pharmaceuticals?

Xeris Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Xeris Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Xeris Pharmaceuticals located?

Xeris Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Xeris Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Xeris Pharmaceuticals from 12/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/4/2024.

When did Xeris Pharmaceuticals pay the last dividend?

The last dividend was paid out on 12/4/2024.

What was the dividend of Xeris Pharmaceuticals in the year 2023?

In the year 2023, Xeris Pharmaceuticals distributed 0 USD as dividends.

In which currency does Xeris Pharmaceuticals pay out the dividend?

The dividends of Xeris Pharmaceuticals are distributed in USD.